Antisickling Activity Evaluation of Fractions Obtained From Whole Extracts of Newbouldia Laevis P. Beauv (Bignoniaceae)

Abstract

Objective: This study aims to evaluate the fractions from whole extracts of roots and stem barks of Newbouldia laevis and their effect on sickling.
 Methods: Hydroethanolic extracts of stem barks and roots of Newbouldia laevis were fractionated by the technics of cold precipitation in ethanol. The fractions obtained after phytochemical screening were subjected to Emmel test to evaluate their anti-sickling activity. Active fractions were tested for DPPH and AAPH assay (AAPH induced membrane lipoperoxidation and evaluation of reduction of hemolysis).
 Results: Two fractions were obtained from each whole extract: supernatant and pellet fractions. Supernatants fractions obtained from whole roots barks extract and stem barks extract at a concentration of 30 mg/ml reduced sickling up respectively to 7% and 10% against 86% for the control. Pellets fractions obtained from the both extracts induced coagulation of SS blood at 30 mg/ml against 86% for the control.
 Conclusion: Supernatants fractions of hydroethanolic whole extract of roots and stem backs of Newbouldia laevis promise as the potential source of active molecules against sickle cell disease.

Effect of Concomitant Hydroxyurea Therapy with Rutin and Gallic Acid: Integration of Pharmacokinetic and Pharmacodynamic Approaches

“…It is an anticancer drug and, therefore, there are liabilities as well, like myelosuppression. Hence, for any candidates that are to be used as phytotherapeutics, like rutin (native form as well as its aglycone) , or gallic acid (enriched in extracts) , which are reported to have an antisickling effect, it is prudent to investigate their potential to combat HU-induced toxicities. In this direction, we evaluated the individual effects of rutin and gallic acid along with HU against the myelosuppressive pitfall of HU.…”

“…Therefore, current studies are focused on the symptomatic management of patients, mainly pain crisis, and decrease the frequency of hospitalization period . Recently, l -glutamine has been approved by the USFDA for reducing the severe complications in SCA patients via reduction of oxidative stress. , Several phytoconstituents/amino acids/botanical drugs have been investigated using in vitro and in vivo preclinical/clinical models for their effectiveness by targeting improvement in the pathophysiology of SCA. , The examples are as follows: curcumin, phenylalanine, cajaminose, limonoid, lunularic acid, epigallocatechin gallate, vanillin, SCD-101, NIPRISAN, resveratrol, angelicin, cucurbitacin, dimethyl butyrate, l -arginine, gum arabic, docosahexaenoic acid, and so forth. ,− Under these circumstances, the present study deals with the individual effects of two important phytoconstituents, namely, rutin and gallic acid (Figure ), which have several useful pharmacological properties. − Rutin and its aglycone (quercetin) are reported for their function as antisickling agents. , Newboludia laevis and Combretum glutinosum are reported to have an antisickling activity where gallic acid is the most active phytoconstituent. , Hence, it would be beneficial to elucidate if any alteration in the pharmacokinetics of HU in the presence of rutin or gallic acid occurred. This investigation can generate information on precipitation of drug-induced toxicities, therapeutic failure, or safe co-administration depending upon the type of pharmacokinetic interaction, namely, positive, negative, or no interaction. , On the other hand, it would be useful to elucidate their pharmacological actions along with HU in counteracting HU-induced myelosuppression.…”

“…19,20 Newboludia laevis and Combretum glutinosum are reported to have an antisickling activity where gallic acid is the most active phytoconstituent. 21,22 Hence, it would be beneficial to elucidate if any alteration in the pharmacokinetics of HU in the presence of rutin or gallic acid occurred. This investigation can generate information on precipitation of drug-induced toxicities, therapeutic failure, or safe co-administration depending upon the type of pharmacokinetic interaction, namely, positive, negative, or no interaction.…”